Table 1 Baseline patient, tumor, and treatment characteristics according to histological tumor type
Total (n = 7236) | NST (n = 6284) | ILC (n = 952) | P value* | ||||
|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
Study | < 0.001 | ||||||
SUCCESS A | 3479 | 48,1 | 3060 | 48.7 | 419 | 44.0 | |
SUCCESS B (HER2neu positive only) | 320 | 4.4 | 294 | 4.7 | 26 | 2.7 | |
SUCCESS C (HER2neu negative only) | 3437 | 47.5 | 2930 | 46.6 | 507 | 53.3 | |
Age (years) | < 0.001 | ||||||
Mean ± SD | 54.3 ± 10.3 | 53.9 ± 10.4 | 56.7 ± 9.3 | ||||
Median value | 54.0 | 54.0 | 57.0 | ||||
Range | 22–86 | 22–86 | 29–85 | ||||
Age category (years) | < 0.001 | ||||||
≤ 50 | 2733 | 37.8 | 2460 | 39.1 | 273 | 28.7 | |
51–65 | 3274 | 45.2 | 2785 | 44.3 | 489 | 51.4 | |
> 65 | 1229 | 17.0 | 1039 | 16.5 | 190 | 20.0 | |
BMI (kg/m2) | 0.164 | ||||||
Mean ± SD | 26.5 | 26.5 ± 5.2 | 26.6 ± 4.9 | ||||
Median value | 25.5 | 25.5 | 2.6 | ||||
Range | 15.4–53.9 | 15.4–53.9 | 16.6–48.7 | ||||
BMI category (kg/m2) | 0.670 | ||||||
< 18.5 | 87 | 1.2 | 74 | 1.2 | 13 | 1.4 | |
18.5–24.99 | 3227 | 44.6 | 2818 | 44.8 | 409 | 43.0 | |
25–29.99 | 2315 | 32.0 | 2007 | 31.9 | 308 | 32.4 | |
≥ 30 | 1607 | 22.2 | 1385 | 22.0 | 222 | 23.3 | |
Menopausal status | < 0.001 | ||||||
Premenopausal | 2911 | 40.2 | 2598 | 41.3 | 313 | 32.9 | |
Postmenopausal | 4325 | 59.8 | 3686 | 58.7 | 639 | 67.1 | |
Surgical treatment | < 0.001 | ||||||
BET | 5257 | 72.7 | 4743 | 75.5 | 514 | 54.0 | |
Mastectomy | 1800 | 24.9 | 1389 | 22.1 | 411 | 43.2 | |
Other | 179 | 2.5 | 152 | 2.4 | 27 | 2.8 | |
Tumor size (pT) | < 0.001 | ||||||
pT1 | 3117 | 43.1 | 2858 | 45.5 | 259 | 27.2 | |
pT2 | 3659 | 50.6 | 3139 | 50.0 | 520 | 54.6 | |
pT3 | 361 | 5.0 | 205 | 3.3 | 156 | 16.4 | |
pT4 | 96 | 1.3 | 79 | 1.3 | 17 | 1.8 | |
Missing | 3 | 0.0 | 3 | 0.0 | 0 | 0.0 | |
Nodal status (pN) | < 0.001 | ||||||
pN0 | 2746 | 37.9 | 2454 | 39.1 | 292 | 30.7 | |
pN1 | 3343 | 46.2 | 2904 | 46.2 | 439 | 46.1 | |
pN2 | 805 | 11.1 | 682 | 10.9 | 123 | 12.9 | |
pN3 | 332 | 4.6 | 235 | 3.7 | 97 | 10.2 | |
Missing | 10 | 0.1 | 9 | 0.1 | 1 | 0.1 | |
Nodal status category (pN) | < 0.001 | ||||||
pN0/pN1 | 6089 | 84.1 | 5358 | 85.3 | 731 | 76.8 | |
pN2/pN3 | 1137 | 15.7 | 917 | 14.6 | 220 | 23.1 | |
Missing | 10 | 0.1 | 9 | 0.1 | 1 | 0.1 | |
Hormone receptor (HR) status | < 0.001 | ||||||
Negative (ER and PR negative) | 1873 | 25.9 | 1815 | 28.9 | 58 | 6.1 | |
Positive (ER and/or PR positive) | 5362 | 74.1 | 4468 | 71.1 | 894 | 93.9 | |
Missing | 1 | 0.0 | 1 | 0.0 | 0 | 0.0 | |
Estrogen receptor (ER) status | < 0.001 | ||||||
Negative | 2070 | 28.6 | 1990 | 31.7 | 80 | 8.4 | |
Positive | 5163 | 71.4 | 4292 | 68.3 | 871 | 91.5 | |
Missing | 3 | 0.0 | 2 | 0.0 | 1 | 0.1 | |
Progesterone receptor (PR) status | < 0.001 | ||||||
Negative | 2599 | 35.9 | 2435 | 38.7 | 164 | 17.2 | |
Positive | 4633 | 64.0 | 3846 | 61.2 | 787 | 82.7 | |
Missing | 4 | 0.1 | 3 | 0.0 | 1 | 0.1 | |
HER2neu-status | < 0.001 | ||||||
Negative | 6007 | 83.0 | 5133 | 81.7 | 874 | 91.8 | |
Positive | 1166 | 16.1 | 1095 | 17.4 | 71 | 7.5 | |
Missing | 63 | 0.9 | 56 | 0.9 | 7 | 0.7 | |
Grading | < 0.001 | ||||||
G1 | 379 | 5.2 | 346 | 5.5 | 33 | 3.5 | |
G2 | 3595 | 49.7 | 2852 | 45.4 | 743 | 78.0 | |
G3 | 3259 | 45.0 | 3085 | 49.1 | 174 | 18.3 | |
Missing | 3 | 0.0 | 1 | 0.0 | 2 | 0.2 | |
Biological subtype | < 0.001 | ||||||
Luminal A (HR+/HER2neu−/G1-2) | 3194 | 44.1 | 2489 | 39.6 | 705 | 74.1 | |
Luminal B (HR+/HER2neu−/G3) | 1386 | 19.2 | 1258 | 20.0 | 128 | 13.4 | |
HER2neu type (HER2neu+) | 1166 | 16.1 | 1095 | 17.4 | 71 | 7.5 | |
Triple negative (HR-/HER2neu-) | 1426 | 19.7 | 1386 | 22.1 | 40 | 4.2 | |
Missing | 64 | 0.9 | 56 | 0.9 | 8 | 0.8 | |
Chemotherapy | 0.005 | ||||||
FEC-Doc (all SUCCESS studies) | 3628 | 50.1 | 3153 | 50.2 | 475 | 49.9 | |
FEC-DocG (SUCCESS A and B) | 1884 | 26.0 | 1668 | 26.5 | 216 | 22.7 | |
Doc-C (SUCCESS C only) | 1724 | 23.8 | 1463 | 23.3 | 261 | 27.4 | |
Endocrine therapy | 0.008 | ||||||
No | 3956 | 54.7 | 3476 | 55.3 | 480 | 50.4 | |
Yes | 3267 | 45.1 | 2801 | 44.6 | 466 | 48.9 | |
Missing | 13 | 0.2 | 7 | 0.1 | 6 | 0.6 | |
HER2-targeted therapy | < 0.001 | ||||||
No | 6384 | 88.2 | 5483 | 87.3 | 901 | 94.6 | |
Yes | 839 | 11.6 | 794 | 12.6 | 45 | 4.7 | |
Missing | 13 | 0.2 | 7 | 0.1 | 6 | 0.6 | |
Radiotherapy | < 0.001 | ||||||
No | 1096 | 15.1 | 918 | 14.6 | 178 | 18.7 | |
Yes | 6127 | 84.7 | 5359 | 85.3 | 768 | 80.7 | |
Missing | 13 | 0.2 | 7 | 0.1 | 6 | 0.6 | |
Bisphosphonate therapy | 0.016 | ||||||
No | 3876 | 53.6 | 3334 | 53.1 | 542 | 56.9 | |
Yes | 3347 | 46.3 | 2943 | 46.8 | 404 | 42.4 | |
Missing | 13 | 0.2 | 7 | 0.1 | 6 | 0.6 | |